Rodrigo Fresco

Montevideo, MO, Uruguay

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.

Journal: JAMA oncology

Published: September 25, 2025

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 21, 2024

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

Journal: The New England journal of medicine

Published: March 20, 2024

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.

Journal: Therapeutic advances in medical oncology

Published: March 08, 2023

Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced Malignancy.

Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced Malignancy.

Journal: Clinical breast cancer

Published: October 31, 2018

The Authors Respond.

The Authors Respond.

Journal: Epidemiology (Cambridge, Mass.)

Published: May 18, 2018

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

Journal: The Lancet. Oncology

Published: July 03, 2017

Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study.

Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 19, 2017

Final Survival Analysis of ROSE/TRIO-012.

Final Survival Analysis of ROSE/TRIO-012.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 03, 2016

EPIDEMIOLOGY AND TREATMENT OF MONTEGGIA LESION IN ADULTS: SERIES OF 44 CASES.

EPIDEMIOLOGY AND TREATMENT OF MONTEGGIA LESION IN ADULTS: SERIES OF 44 CASES.

Journal: Acta ortopedica brasileira

Published: March 22, 2016

Reply to H.J. Lee et al.

Reply to H.J. Lee et al.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 22, 2015

Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials.

Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials.

Journal: The oncologist

Published: August 04, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026